Can Shohei Ohtani Win NL MVP And NL Cy Young In The Same Season?
One half of this market is close to a formality; the other half has never happened in the history of baseball. Kalshi's Ohtani award combo asks whether he can be the National League's MVP while also being its best pitcher in 2026, and the distance between those two legs is the whole story. Watching Ohtani take NL MVP and NL Cy Young in the same year would be the rarest thing MLB has to offer, and the contract is priced like it. Three rows in the model panel below settle how much of this market is really about the arm and not the bat, and the ratio they produce is roughly three to one. We will come back to it.
In Summary
- The Kalshi Ohtani sweep market pays only if he wins both the NL MVP and the NL Cy Young for 2026. One award without the other resolves NO.
- YES has traded around 4¢, about 4% implied, or roughly +2400 in American odds.
- Our seven-model panel blends to 4%, dead even with the market, which is as close to agreement as this board gets.
- The three panelists who priced the two legs separately all put the arm far below the bat: a Cy Young leg of 6% to 15% against an MVP leg of 20% to 40%.
- Nobody has ever won MVP primarily as a hitter and taken the Cy Young in the same season. Pitchers have swept both; a designated hitter who moonlights as a starter has not.
The Market
| Venue | Kalshi — a CFTC-regulated exchange (18+; availability varies by state, as of July 2026) |
| The Contract | Resolves per the market's official settlement rules: Shohei Ohtani wins National League Cy Young and National League MVP |
| Current YES Price | 4¢ (+2400 American) ≈ 4% implied (as of July 21, 2026) |
Event contracts settle on a stated outcome rather than a point spread, which is why the fine print does more work here than the price does. If that mechanic is new to you, how prediction markets work covers the settlement side before you read another cent figure on this page.
The Bull Case (Why YES)
Start with the leg nobody doubts. When Ohtani is healthy, MVP voters have shown they will hand him the award on his bat alone; he has won it in both leagues, including on unanimous ballots, and no everyday hitter matches his combination of power, speed, and lineup presence.
The Cy Young leg is harder, but the steelman is real: on a per-inning basis his stuff has always graded out near the top of the sport, and awards voting has drifted toward run-prevention rates and away from raw innings totals. If the Dodgers let his pitching workload build through the summer and he dominates while carrying it, voters get the most irresistible narrative baseball can offer: the first man to be his league's best hitter and best pitcher in the same year. Voters make history when history is on the ballot.
The Bear Case (Why NO)
This is a parlay, and the second leg does the damage. Cy Young voting still rewards volume: winners are almost always full-season aces who take the ball every fifth day and pile up innings. A two-way player's arm is managed by design, and the Dodgers' incentive is October, not November hardware; they gain nothing by stretching Ohtani's workload to chase an award.
His elbow has already been surgically rebuilt, so any midseason soreness kills the pitching case instantly even if the bat stays elite. The first leg is not free either: MVP races can swing on a rival's monster season or a story voters find fresher. To cash, one body has to survive six months doing two jobs while beating every specialist at his own job. There is a reason no hitter-first two-way player has ever done it.
Worked Example: Turning 4¢ Into A Real Probability
Cents are the least useful way to think about a longshot, so convert before you judge it. A Kalshi contract settles at $1 if it resolves YES. Buy at 4¢ and you are risking 4 to make 96, which is 24-to-1, or +2400 in American odds. The implied probability is simply the price: 4¢ = 4%. Our panel also says 4%. Read that as the market and the models shaking hands rather than as an edge, because a longshot the models agree with is still a longshot. The cents-to-odds conversion is the first habit worth building on any exchange.
Now the numbers I promised. Three panelists showed their work on the two legs separately, and their splits are far more useful than the joint figure:
| Model | MVP leg | NL Cy Young leg |
|---|---|---|
| ChatGPT | 25–35% | 8–12% |
| GLM 5.2 | 20% | 15% |
| Kimi K3 | ~40% | ~6% (its joint, since it treats the sweep as the Cy Young leg) |
The row that does the most work is Kimi's, because of the logic underneath it: if Ohtani were good enough to win a Cy Young as a two-way player, he would almost certainly win the MVP too, so the sweep collapses to a single question about the arm. Take the middle of each column, call it a 30% bat and a 10% arm, and multiply:
30% × 10% = 3%
Nudge that up for the correlation ChatGPT flags, since one healthy season feeds both legs, and you land within a point of both the market's 4¢ and the panel's 4% blend. The bat leg is roughly three times the arm leg, and that ratio is the entire contract: what this market doubts is not the hitter, it is whether a managed arm can outpitch every full-time ace in the National League.
The panelists who split the two legs put the arm around one in ten, against a bat closer to one in three. That ratio is the market.
There is a second way to price this that most readers skip. Sportsbooks usually post NL MVP and NL Cy Young as separate season-award futures, DraftKings, FanDuel, and BetMGM included, and an award board carries far more vig than a game line does. Run each side through an EV calculator to de-vig it, multiply the two no-vig probabilities, and you have a sportsbook-derived version of the same joint estimate to hold against Kalshi's single 4¢ contract. Do it across several books and the spread between them tells you more about where the real number sits than any one price will. That habit is just line shopping, the same discipline the live odds screen is built for on game lines, carried over to a futures board.
What The Market Is Pricing
YES has traded around 4 cents with a wide spread beneath it, so the market calls this a longshot while conceding it is a live one. That looks like the right shape. The likeliest 2026 script has Ohtani hitting like an MVP contender all year while pitching well inside a workload the Dodgers deliberately cap, which leaves the Cy Young to a conventional ace with a bigger innings total. We price that leg on its own in the standalone Ohtani Cy Young verdict, and it is the cheaper of the two contracts for exactly the reason this one is cheap.
Both awards are BBWAA votes announced after the season ends, the same machinery that settles the Murakami Rookie of the Year market, and this market needs his name on both of them to resolve YES. The path runs through a full, healthy starter's load deep into September and no NL pitcher running away with the race. Possible, historic if it happens, and priced accordingly.
Model Verdicts
Market: 4¢ (+2400 American) · AI blend: 4%, dead even with the market.
| Model | YES | Why |
|---|---|---|
| ChatGPT | 3% | The Cy Young is the bottleneck because Ohtani must combine elite run prevention with sufficient innings after repeated elbow surgery. |
| Gemini Flash | 1% | Ohtani is not pitching in 2026 due to injury, making Cy Young impossible, and MVP highly improbable. |
| Gemini Pro | 4% | The 4% market price strongly implies Ohtani is trailing in at least one of the award races by late July, making the dual-award feat highly improbable. |
| Grok 4.5 | 5% | Extremely rare dual award feat requires elite pitching and hitting simultaneously amid mid-season uncertainty and strong competition. |
| DeepSeek V4 | 5% | Ohtani is a unique two-way superstar, but winning both awards requires historic, simultaneous pitching and hitting dominance; the 4% market price reflects this extreme difficulty. |
| Kimi K3 | 6% | The conjunction's binding constraint is the Cy Young: Ohtani must outpitch Skenes and Yamamoto over a full season despite the Dodgers' carefully managed workload and innings limits. |
| GLM 5.2 | 4% | Winning both Cy Young and MVP in the same season is historically rare, requiring elite two-way dominance across a full season. |
| Blended Verdict | 4% | equal-weight mean of 7 models (method always disclosed) |
The models span a 5-point range, from Gemini Flash's 1% to Kimi's 6%. The most interesting row is neither the highest nor the lowest, though. It is Gemini Pro's 4%, where the stated reasoning leans on the market price itself to infer that Ohtani must be trailing one of the races. Gemini Pro leans hardest on that crutch, but it is not alone: DeepSeek and Kimi both reach for the 4¢ price in their own answers. A model reading the scoreboard instead of the game is the most common failure we see once a panelist has been shown the number it is supposed to beat.
Model estimates generated 2026-07-21 00:17 UTC. These are model estimates, not predictions of fact and not financial or trading advice. Models are frequently wrong; the market price reflects real traders' money.
The Full Reasoning
ChatGPT (3%): The conjunction is much less likely than another Ohtani MVP: his exceptional hitting and two-way value make him a perennial MVP candidate, but winning the Cy Young requires both ace-level performance and a workload comparable to leading starters. Ohtani has never won a Cy Young, previously peaked near the top of voting, and enters his age-32 season with two major elbow surgeries behind him, increasing innings and durability risk. Historically, winning both awards is extremely rare—only a few pitchers have done so—and Ohtani's path is unusual because his batting could secure MVP even if his pitching falls short. Before incorporating live 2026 performance, I would roughly assign him a 25–35% MVP chance and an 8–12% Cy Young chance; positive correlation through health and overall excellence puts the joint probability around 3%, rather than their simple product. I am most uncertain about his current innings, velocity, run prevention, and competition because I lack reliable live 2026 statistics. The single most estimate-changing news would be that he currently leads NL pitchers in both innings and an ERA-based value metric while remaining healthy.
Gemini Flash (1%): The strongest driver for a 'No' resolution is Ohtani's elbow injury. He underwent surgery in September 2023 and is not expected to pitch in 2024 or 2025. While 2026 is further out, it's highly improbable he would return to elite pitching form, win a Cy Young, and simultaneously win MVP in his first year back from such a significant injury, especially given the typical recovery timelines and the need for a full season of both hitting and pitching dominance. Base rates for players winning both awards are extremely low, and no player has ever done so in the NL. Ohtani's previous success in the AL is not directly transferable to the NL Cy Young. I am most uncertain about the exact timeline of his pitching return and his performance level upon return. The one piece of news that would most change my estimate is an official announcement from the Dodgers or Ohtani himself stating he will be a full-time, two-way player pitching at an elite level for the entire 2026 season.
Gemini Pro (4%): The primary driver of this estimate is the current market price of 4%, which reflects mid-season realities as of July 2026. Winning both the MVP and Cy Young awards in the same season is historically rare; while Ohtani possesses the unique two-way ability to achieve this, he has never won a Cy Young award. By late July, the baseball season is over halfway complete, meaning award races are taking definitive shape. A 4% implied probability suggests Ohtani is likely trailing significantly in at least one of the two races, possibly due to load management, pitching performance not matching the league's top aces, or injury limitations. The base rate for any player winning both awards is extremely low, and doing so requires leading the league in pitching while maintaining elite offensive production. I am most uncertain about Ohtani's exact 2026 statistical splits and health status as of today. The one piece of news that would most change my estimate would be an official announcement of a season-ending injury to Ohtani or the current Cy Young frontrunners suddenly struggling.
Grok 4.5 (5%): Key drivers: dual Cy Young+MVP wins are historically rare (only ~10-15 pitcher instances ever, none by two-way stars recently); Ohtani's unique profile boosts odds if healthy and dominant in both roles for Dodgers, but mid-2026 form, workload limits, and NL rivals (pitchers like Skenes or hitters like Betts/Judge equivalents) suppress it. Base rates favor specialists; pitchers win MVP ~10-20% of years, dual same-year ~5% conditional. Most uncertain: actual 2026 stats/injuries unknown beyond general knowledge of his post-2024 recovery trajectory. The one news that would most change estimate is dominant first-half pitching ERA under 2.50 with 15+ HRs.
DeepSeek V4 (5%): Key drivers (in order): (1) Ohtani's 2026 pitching performance to date—he must be a top-2 NL Cy Young candidate in ERA, strikeouts, and innings; (2) his hitting performance—he must be among the NL's top MVP candidates in offensive value; (3) voter willingness to award both prizes to one player, which historically happens only a few times per century and never for a two-way player; (4) competition—a standout season from another pitcher or position player could split the vote. As of July 21, 2026, roughly 60% of the season is complete, so his current stats heavily shape the probability. Base rate: since 1956, only 11 pitchers have won MVP and Cy Young in the same year, all in the AL/NL format. Ohtani's 2024 MVP as a DH shows he can win MVP without pitching, but adding a Cy Young–caliber season on the mound is a far higher bar. I'm most uncertain about his exact 2026 stats and health; a minor injury or slight dip in performance would drop chances to near zero. The single piece of news that would most change this estimate: if Ohtani currently leads the NL in both pitching fWAR and offensive fWAR by a significant margin.
Kimi K3 (6%): Dominant driver: this is a conjunction, and the Cy Young leg is binding—if Ohtani won NL Cy Young as a two-way star, he would almost surely win MVP too, so p(YES) approximates p(Cy Young). Working against him: the Dodgers heavily manage his innings (roughly 47 regular-season innings in his 2025 return), the March 2026 WBC may further constrain his ramp-up, and competition is elite (Paul Skenes, 2025 NL Cy Young winner; teammate Yoshinobu Yamamoto). His best full pitching season (2022: 2.33 ERA, 166 IP) finished only fourth in Cy Young voting. On the MVP side he is strong—three straight MVPs (2023–25), and voters reward two-way uniqueness—so that leg alone might be ~40%. Base rates: non-favorite pitchers win the Cy Young perhaps 5–10% of the time. My biggest uncertainty is lacking verified 2026 first-half statistics; the 4¢ (+2400 American) price itself suggests he isn't the current frontrunner. Most decision-relevant news: Ohtani leading NL pitchers in ERA/fWAR at the All-Star break.
GLM 5.2 (4%): Key drivers: (1) Joint probability of winning two awards is very low. Only a few players have ever won both Cy Young and MVP in the same season (Verlander 2011, Kershaw 2014). (2) Ohtani is uniquely positioned as an elite two-way player, but has never won a Cy Young even in his best pitching seasons. (3) I lack specific 2026 season data — Ohtani's current health, pitching workload, and performance are unknown to me, which is my biggest uncertainty. (4) If he returned to pitching in 2025 after Tommy John recovery, he could be fully ramped up by 2026, but NL Cy Young competition is deep (Skubal, Sale, Wheeler, etc.). (5) Even if he has a 15% chance at Cy Young and 20% at MVP, the joint probability with some positive correlation might be 3-6%. The market at 4% appears efficient given the rarity of this double. The one piece of news that would most change my estimate: confirmation that Ohtani is actively pitching in 2026 with elite stats in both categories as of mid-season.
How We Grade The Models
A verdict table is only worth reading if somebody keeps score, so every model on this panel is also back-tested against markets that have already settled. The forecasters answer, the market resolves, and each model gets graded against the outcome and against the market's own closing price. That second comparison is the honest bar, because a model that quietly repeats the price back at you looks accurate without knowing anything, which is exactly what Gemini Pro's reasoning does on this page. A model only earns a recommendation from us once it beats the market on questions it has never seen, across enough of them that the gap is not noise.
Keeping score also means saying out loud where these answers are wrong, and this market gave us three. Gemini Flash reasoned from a premise that Ohtani is not pitching in 2026 at all, which would make the Cy Young leg impossible rather than merely hard, and that stale premise is why its 1% sits so far below the rest of the board. GLM 5.2 lists Tarik Skubal among the NL competition; he pitches in the American League. DeepSeek's line that all 11 MVP-plus-Cy-Young sweeps came in the modern league-specific format is not right either, since the Cy Young was a single MLB-wide award until 1967. We print every answer exactly as the model gave it, errors included. A panel that quietly edits or deletes its worst rows is not a panel worth paying attention to, and a reader who can see which model was working from bad information knows how much weight to put on the rest.
What Would Move This Market
Come back to the 10% arm. Because that leg is so small, hitting-side news moves this contract far less than it feels like it should. Run it: a monster August that dragged the MVP leg from 30% all the way up to 50% still only carries the joint estimate from about 3% to about 5%, and 5% is another way of saying longshot.
The re-pricing news is all workload and health: Ohtani stretched to a full starter's turn every fifth day through August, a September innings total that stops looking managed, or the reverse: a skipped start, a forearm note in a beat report, an early hook. On the competition side, watch whether Paul Skenes or Yoshinobu Yamamoto separates from the NL field, since a runaway favorite closes this door faster than anything Ohtani does. If you want to track the same market where the real money moves it, how to trade MLB on Kalshi covers the mechanics. Our read is that the market has this one about right, and the honest version of that sentence is that a 4¢ longshot priced correctly is still a longshot. The interesting part was never the price. It was learning that the bat was never the question.
FAQ
Is Kalshi legal in my state?
Availability varies by state and changes over time. Kalshi is a federally regulated exchange, but eligibility differs by jurisdiction, so check your eligibility directly on the platform before trading, and see are prediction markets legal for the current state-by-state picture. You must be 18 or older. Current as of July 2026.
Are the model verdicts advice?
No. Model verdicts are statistical estimates of how a market might resolve, not financial advice. They can be wrong, markets move, and every trading decision is your own.
Is it possible to win MVP and the Cy Young in the same season?
Yes. Pitchers have swept both awards before, with Justin Verlander in 2011 and Clayton Kershaw in 2014 among the most recent examples. What has never happened is a player winning MVP primarily as a hitter while also taking the Cy Young, which is exactly what this market asks of Ohtani.
Are both awards required for this market to resolve YES?
Yes. Ohtani must win both the National League MVP and the National League Cy Young for the 2026 season. If he wins one award and not the other, the market resolves NO, per the market's settlement rules.
